Two phase III trials of bimekizumab for the treatment of moderate-to-severe hidradenitis suppurativa: a critically appraised research paper

British Journal of Dermatology 2026

View at publisher
Authors: Rebecca McCarthy, Hans Christian Ring
DOI: 10.1093/bjd/ljag051
Cited by: 0
References: 8

Abstract

This article presents a critical appraisal of ‘Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE-HEARD I and BE-HEARD II): two 48-week, randomized, double-blind, placebo-controlled, multicentre phase III trials’.

Fields of Study & Subjects

Hidradenitis Suppurativa and Treatments Autoimmune and Inflammatory Disorders Acne and Rosacea Treatments and Effects

Publication details

Journal / source
British Journal of Dermatology
Volume
194
Issue
6
Pages
1064–1066
Publication date
12 February 2026
Language
EN